Adeno-associated virus vectors for gene therapy: more pros than cons?
- 1 November 2000
- journal article
- review article
- Published by Elsevier in Molecular Medicine Today
- Vol. 6 (11), 433-440
- https://doi.org/10.1016/s1357-4310(00)01810-4
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- The Use of Adeno-Associated Virus to Circumvent the Maturation-Dependent Viral Transduction of Muscle FibersHuman Gene Therapy, 2000
- High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and CapGene Therapy, 1999
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectorsGene Therapy, 1999
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1996
- Risk Potential of the Chromosomal Insertion of Foreign DNAAnnals of the New York Academy of Sciences, 1995
- SAFETY ASPECTS OF GENE THERAPYBritish Journal of Haematology, 1992